Actively Recruiting
EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
Led by Niguarda Hospital · Updated on 2026-04-16
100
Participants Needed
1
Research Sites
284 weeks
Total Duration
On this page
Sponsors
N
Niguarda Hospital
Lead Sponsor
N
Neuravi Limited
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.
CONDITIONS
Official Title
EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Large vessel occlusion on CTA or MRA in anterior or posterior proximal cerebral vessels up to A1, M1, dominant M2, or P1
- ASPECTS score 6 or greater
- Mismatch or good collaterals shown on MR, multiphasic CTA, or perfusion CT
- Groin puncture performed within 12 hours from symptom onset
- Use of EmboTrap�AE II Revascularization Device (Neuravi) as first or second line treatment
You will not qualify if you...
- Informed consent not given
- Presence of extracranial or tandem occlusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ASST GOM Niguarda
Milan, Italy, 20162
Actively Recruiting
Research Team
E
Edoardo Boccardi, MD
CONTACT
L
Luca Valvassori, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here